Michael Joseph, MD
Rheumatology · Joplin, MONPI 1902919178
Payments from drug & device makers
Across 593 payments — averaging $159.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apria Healthcare LLC$85K
- Amgen$2K
- GSK$1K
- Pfizer$902
- Mallinckrodt Hospital Products Inc.$812
- AbbVie$642
- plus $3K from 27 others
What the payments were for
- Speaking & faculty fees$85,26090%
- Food & beverage$8,9509%
- Education$1570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apria Healthcare LLC | 13 | $85,260 |
| Amgen(2 entities) | 163 | $2,332 |
| GSK | 96 | $1,334 |
| Pfizer | 61 | $902 |
| Mallinckrodt Hospital Products Inc. | 34 | $812 |
| AbbVie | 35 | $642 |
| Novartis | 33 | $541 |
| Johnson & Johnson | 24 | $447 |
| E.r. Squibb & Sons, L.L.C. | 34 | $395 |
| Octapharma USA, Inc. | 7 | $264 |
| AstraZeneca | 16 | $254 |
| Mallinckrodt Enterprises LLC | 11 | $190 |
| Genentech USA, Inc. | 13 | $170 |
| Radius Health, Inc. | 9 | $147 |
| Merck | 6 | $83 |
| Shire North American Group Inc | 6 | $78 |
| UCB, Inc. | 3 | $74 |
| ANI Pharmaceuticals, Inc. | 4 | $71 |
| Sanofi | 3 | $65 |
| CSL Behring | 3 | $52 |
| Grifols USA, LLC | 3 | $48 |
| Boehringer Ingelheim | 3 | $46 |
| Kaleo, Inc. | 2 | $25 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Sandoz | 1 | $24 |
| Bayer | 1 | $18 |
| Fresenius Kabi USA, LLC | 1 | $14 |
| Optinose US, Inc. | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
| Hospira, Inc. | 1 | $9 |
| Organon | 1 | $8 |
| Bio Products Laboratory USA, Inc. | 1 | $3 |
How this compares
$94,368 in reported general payments places this provider in the 85th percentile of 134 rheumatology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xeljanz XrTofacitinib Citrate | 53 | $365,428 |
| Enbrel SureclickEtanercept | 30 | $360,797 |
| Humira(Cf) PenAdalimumab | 33 | $278,495 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 21 | $261,565 |
| Simponi AriaGolimumab | 30 | $242,114 |
| RinvoqUpadacitinib | 26 | $169,619 |
| ActemraTocilizumab | 46 | $161,363 |
| EnbrelEtanercept | 11 | $126,793 |
| Humira PenAdalimumab | 15 | $120,287 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $87,483 |
| Repatha SureclickEvolocumab | 74 | $81,247 |
| TymlosAbaloparatide | 27 | $71,090 |
| MounjaroTirzepatide | 37 | $34,975 |
| FarxigaDapagliflozin Propanediol | 58 | $33,947 |
| Praluent PenAlirocumab | 19 | $23,158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $52 | $261,56521 claims |
| Johnson & JohnsonSimponi Aria | $447 | $242,11430 claims |
| AbbVieRinvoq | $642 | $169,61926 claims |
| AmgenEnbrel | $2,332 | $126,79311 claims |
| Radius Health, Inc.Tymlos | $147 | $71,09027 claims |
| AstraZenecaFarxiga, Symbicort | $254 | $40,63887 claims |
| Lilly USA, LLCMounjaro | $12 | $34,97537 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,334 | $31,03357 claims |
| PfizerPremarin, Abrysvo | $902 | $9,59831 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $24 | $4,05611 claims |
| MerckDulera | $83 | $3,68111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 134 rheumatology providers in Missouri.
Other rheumatology in Joplin
- Justin ReedJoplin$4K
- John ErvinKansas City$18.7M
- David TrueSpringfield$15.8M
- Ghaith NoaisehKansas City$1.6M
- Anne WinklerCarthage$1.6M
- Alfred KimSaint Louis$1.2M
- Tina ShahKansas City$1.2M
- Sona KamatSaint Louis$931K
- Akgun InceSaint Louis$849K
- Adam KilianSaint Louis$593K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.